During this webinar Dr. Morten Frost will discuss incretin hormone-based therapies of common conditions including type 2 diabetes and obesity are rapidly emerging. While preclinical studies indicate that GLP-1 advances bone formation and GIP decreases bone resorption, clinical studies based on early GLP-1 receptor agonists show neutral effects on bone. However, more recent GLP-1 and GIP receptor agonist have dramatic effects on body weight which may have skeletal implications. In the webinar, I will review currently available clinical data and discuss potential effects of incretin-based therapies.
